- The FDA accepts for review Acorda Therapeutics' (NASDAQ:ACOR -0.8%) refiled New Drug Application (NDA) seeking approval for inhaled INBRIJA (levodopa) for the treatment of OFF periods in Parkinson's disease (PD) patients currently on a carbidopa/levodopa regimen. The agency's action date is October 5.
- An OFF period is when PD symptoms reappear when the efficacy of medications wanes or before the patient takes the next dose of levodopa.
- Previously: Acorda refiles U.S. marketing application for Parkinson's med Inbrija; shares up 5% premarket (Dec. 7, 2017)
FDA accepts Acorda's marketing application for Parkinson's med Inbrija, action date October 5
Recommended For You
More Trending News
About ACOR Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ACOR | - | - |
Acorda Therapeutics, Inc. |